Evidence map›Paper›PMID 38531935›Full record

ArticleScientific reports2024

Assessment of hypercholesterolemia prevalence and its demographic variations in the Republic of Kazakhstan.

Mukhtar Kulimbet, Kairat Davletov, Timur Saliev, Dimash Davletov, Berik Dzhumabekov, Bauyrzhan Umbayev, Aigerim Balabayeva, Shynar Tanabayeva, Ildar Fakhradiyev

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Mukhtar KulimbetS.D. Asfendiyarov Kazakh National Medical University, 94, Tole-bi Str., 050020, Almaty, Republic of Kazakhstan.
Kairat DavletovS.D. Asfendiyarov Kazakh National Medical University, 94, Tole-bi Str., 050020, Almaty, Republic of Kazakhstan.
Timur SalievS.D. Asfendiyarov Kazakh National Medical University, 94, Tole-bi Str., 050020, Almaty, Republic of Kazakhstan.
Dimash DavletovS.D. Asfendiyarov Kazakh National Medical University, 94, Tole-bi Str., 050020, Almaty, Republic of Kazakhstan.
Berik DzhumabekovAl-Farabi Kazakh National University, Almaty, Republic of Kazakhstan.
Bauyrzhan UmbayevNational Laboratory Astana, Center for Life Sciences, Nazarbayev University, Astana, Republic of Kazakhstan.
Aigerim BalabayevaS.D. Asfendiyarov Kazakh National Medical University, 94, Tole-bi Str., 050020, Almaty, Republic of Kazakhstan.
Shynar TanabayevaS.D. Asfendiyarov Kazakh National Medical University, 94, Tole-bi Str., 050020, Almaty, Republic of Kazakhstan.
Ildar FakhradiyevS.D. Asfendiyarov Kazakh National Medical University, 94, Tole-bi Str., 050020, Almaty, Republic of Kazakhstan. fakhradiyev.i@kaznmu.kz.
Kazakh National Medical University · KZAl-Farabi Kazakh National University · KZNazarbayev University · KZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypercholesterolemia is a major risk factor for cardiovascular disease, the leading cause of death in Kazakhstan. Understanding its prevalence is vital for effective public health planning and interventions. This study aimed to assess the scale of hypercholesterolemia in the Republic of Kazakhstan and to identify differences among distinct population groups. A cross-sectional study involving 6720 participants (a nationally representative survey.) aged 18-69 was conducted from October 2021 to May 2022 across all 17 regions of Kazakhstan. The magnitude of hypercholesterolemia was 43.5%. Cholesterol levels were determined through blood biochemical analysis. Age, sex, geographic location, and ethnicity served as covariates. The majority of participants (65.49%) were from urban areas with an almost equal gender distribution (50.07% male and 49.93% female). The predominant age groups were 18-29 years (25.71%) and 30-39 years (25.12%), and 65.09% identified as Kazakh. The prevalence increased with age, with the 60-69 age group showing the highest rate at 71.14%. Women had slightly higher rates than men. Geographical differences were evident, with regions like Astana city and Almaty region showing significant disparities. Kazakhs had a lower rate compared to other ethnicities. Age, region, and BMI were significant predictors for hypercholesterolemia in both binary and multivariate logistic regression analyses. The study revealed a significant prevalence of hypercholesterolemia in Kazakhstan, with increasing age as a major determinant. Women, especially those over 50, and certain regions showed higher cholesterol levels. The disparities observed across regions and ethnicities suggest the need for targeted public health interventions to address this pressing health concern.

Indexed as

Central Asian PeopleHypercholesterolemiaAdolescentAdultAgedCholesterolCross-Sectional StudiesFemaleHumansKazakhstanMaleMiddle AgedPrevalenceYoung AdultCholesterolCholesterol levelsHypercholesterolemiaKazakhstanPrevalence

Identifiers

PMID38531935
PMCPMC10966034
OpenAlexW4393189188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.